These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 29479062)

  • 1. Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration.
    Ali AY; Wu X; Eissa N; Hou S; Ghia JE; Murooka TT; Banerji V; Johnston JB; Lin F; Gibson SB; Marshall AJ
    Leukemia; 2018 Sep; 32(9):1958-1969. PubMed ID: 29479062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment.
    Piddock RE; Loughran N; Marlein CR; Robinson SD; Edwards DR; Yu S; Pillinger GE; Zhou Z; Zaitseva L; Auger MJ; Rushworth SA; Bowles KM
    Blood Cancer J; 2017 Mar; 7(3):e539. PubMed ID: 28282033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and function of phosphoinositide 3-kinase delta in mesenchymal stromal cells from normal and leukaemic bone marrow.
    Ali AY; Guan Q; Wu X; Hou S; Banerji V; Johnston JB; Wall D; Szwajcer D; Gibson SB; Marshall AJ
    Br J Haematol; 2019 Jun; 185(5):883-887. PubMed ID: 30873593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection.
    Pillinger G; Loughran NV; Piddock RE; Shafat MS; Zaitseva L; Abdul-Aziz A; Lawes MJ; Bowles KM; Rushworth SA
    Oncotarget; 2016 Jun; 7(26):39784-39795. PubMed ID: 27174919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
    Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
    Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
    Till KJ; Pettitt AR; Slupsky JR
    J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.
    Compagno M; Wang Q; Pighi C; Cheong TC; Meng FL; Poggio T; Yeap LS; Karaca E; Blasco RB; Langellotto F; Ambrogio C; Voena C; Wiestner A; Kasar SN; Brown JR; Sun J; Wu CJ; Gostissa M; Alt FW; Chiarle R
    Nature; 2017 Feb; 542(7642):489-493. PubMed ID: 28199309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
    Hoellenriegel J; Meadows SA; Sivina M; Wierda WG; Kantarjian H; Keating MJ; Giese N; O'Brien S; Yu A; Miller LL; Lannutti BJ; Burger JA
    Blood; 2011 Sep; 118(13):3603-12. PubMed ID: 21803855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
    Balakrishnan K; Peluso M; Fu M; Rosin NY; Burger JA; Wierda WG; Keating MJ; Faia K; O'Brien S; Kutok JL; Gandhi V
    Leukemia; 2015 Sep; 29(9):1811-22. PubMed ID: 25917267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.
    Ma CC; Zhang CM; Tang LQ; Liu ZP
    Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.
    Dong S; Guinn D; Dubovsky JA; Zhong Y; Lehman A; Kutok J; Woyach JA; Byrd JC; Johnson AJ
    Blood; 2014 Dec; 124(24):3583-6. PubMed ID: 25258342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
    Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
    Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
    [No Abstract]   [Full Text] [Related]  

  • 13. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity.
    Funk CR; Wang S; Chen KZ; Waller A; Sharma A; Edgar CL; Gupta VA; Chandrakasan S; Zoine JT; Fedanov A; Raikar SS; Koff JL; Flowers CR; Coma S; Pachter JA; Ravindranathan S; Spencer HT; Shanmugam M; Waller EK
    Blood; 2022 Jan; 139(4):523-537. PubMed ID: 35084470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphatidylinositol 3-kinase β and δ isoforms play key roles in metastasis of prostate cancer DU145 cells.
    Zhang Z; Liu J; Wang Y; Tan X; Zhao W; Xing X; Qiu Y; Wang R; Jin M; Fan G; Zhang P; Zhong Y; Kong D
    FASEB J; 2018 Nov; 32(11):5967-5975. PubMed ID: 29792732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idelalisib.
    Zirlik K; Veelken H
    Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of upregulated phosphoinositide 3-kinase γ as a target to suppress breast cancer cell migration and invasion.
    Xie Y; Abel PW; Kirui JK; Deng C; Sharma P; Wolff DW; Toews ML; Tu Y
    Biochem Pharmacol; 2013 May; 85(10):1454-62. PubMed ID: 23500535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.
    Vangapandu HV; Jain N; Gandhi V
    Expert Opin Investig Drugs; 2017 May; 26(5):625-632. PubMed ID: 28388280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adhesion of ZAP-70+ chronic lymphocytic leukemia cells to stromal cells is enhanced by cytokines and blocked by inhibitors of the PI3-kinase pathway.
    Lafarge ST; Johnston JB; Gibson SB; Marshall AJ
    Leuk Res; 2014 Jan; 38(1):109-15. PubMed ID: 23981382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.
    Fiorcari S; Brown WS; McIntyre BW; Estrov Z; Maffei R; O'Brien S; Sivina M; Hoellenriegel J; Wierda WG; Keating MJ; Ding W; Kay NE; Lannutti BJ; Marasca R; Burger JA
    PLoS One; 2013; 8(12):e83830. PubMed ID: 24376763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.